SUMMARY OF INVENTION
Prostate-specific membrane antigen (PSMA) is a transmembrane glutamate carboxypeptidase that is found in prostate cancers and the neovasculature of most solid tumors, however, it is absent from healthy prostate glands and normal vessels. PSMA, through its role in a complex signaling cascade, promotes prostate cancer progression, as well as vessel formation in tumors (known as neoangiogenesis).
MSK investigators have determined that modulating PSMA levels and enzymatic activity can lead to alterations in cancer cell metabolism and proliferation, as well as tumor oxygenation, through changes in the tumor’s vascular bed. Treating tumors with PSMA inhibitors has been shown both in cells and in vivo to inhibit tumor growth and also to enhance the efficacy of chemotherapeutic drugs (anti-androgens), potentially improving treatment outcomes for prostate cancer patients. Using new PET tracers, PSMA imaging can be used to interrogate these critical signaling pathways in prostate cancer to obtain information on prognosis and therapy success.
This method inhibits both tumor progression and vascularization.
The intended target PSMA has high correlation with prostate cancer; however there is also potential for future application as a method of use targeting tumor vasculature in anti-angiogenic therapy for other cancers mediated by PSMA.
The potential market is large, since prostate cancer is one of the most frequently diagnosed cancers in men, and is the most common cause of cancer-related death after lung cancer. Currently, the incidence rate of prostate cancer in the U.S. is approaching one in six men.
STAGE OF DEVELOPMENT
National phase applications filed in the U.S., Canada, EU, Australia, Japan, and China on April 10, 2017
Jan Grimm, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, MSK
Eileen Flowers, PhD